MorphoSys gives clinical update at Q1

Friday 4 May 2012

MorphySys AG expects to start reporting clinical data on its lead antibody compound, MOR103, in the third quarter of this year. A trial in patients with rheumatoid arthritis will report first, followed in 2013 by data from a trial in multiple sclerosis.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Germany